AstraZeneca plc buy ValueFreak
Start price
11.11.22
/
50%
€124.30
Target price
08.09.26
€165.00
Performance (%)
19.34%
Price
12:58
€142.80
Summary
This prediction is currently active. The BUY prediction by ValueFreak currently has a performance of 19.34%. Dividends of €5.54 are taken into consideration when calculating the performance. This prediction currently runs until 08.09.26. The prediction end date can be changed by ValueFreak at any time. ValueFreak has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| AstraZeneca plc | 8.995% | 8.995% | 4.792% |
| iShares Core DAX® | 2.594% | -1.861% | 13.242% |
| iShares Nasdaq 100 | 3.553% | -2.064% | 38.293% |
| iShares Nikkei 225® | 0.687% | -8.704% | 17.510% |
| iShares S&P 500 | 2.209% | -1.988% | 27.632% |
According to ValueFreak what are the pros and cons of AstraZeneca plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
positive Cash Flow expected
Higher EBIT margin than peer group
Fair valuation
Top Rating
Strong uniques
High Investments for future growth
Valuable balance sheet
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Very capable Management
Very good company culture
Leading role in innovation
Very differentiated customer and product portfolio
Growths much faster than the competition
Sustainability is important
Management is a major shareholder
Small Risks for its business
Very small cyclical dependencies
Well known brand
Very Future proof/growth oriented business model
Market Leader or Top 3
Cons
Low dividend yield expected
Comments by ValueFreak for this prediction
In the thread AstraZeneca plc diskutieren
Meine Buy Einschätzung war hier verloren gegangen.
Heute Q3 Bericht - höhere Umsätze trotz drastischem Rückgang des COVID-19 Geschäftes
https://www.astrazeneca.com/investor-relations/9m-and-q3-2023-results.html
https://www.astrazeneca.com/investor-relations/9m-and-q3-2023-results.html
The Company updates its Total Revenue and Core EPS guidance for FY 2023 at CER, based on the average
foreign exchange rates through 2022.Total Revenue is expected to increase by a mid single-digit percentage (previously low-to-mid single-digit).(previously low double-digit).
- Excluding COVID-19 medicines, Total Revenue is expected to increase by a low-teens percentage
(previously high single-digit to low double-digit).
- Core EPS is expected to increase by a low double-digit to low-teens percentage
An der Börse scheint der Bericht positiv anzukommen.
.
.
Astra Zeneca mit gutem Start in das neue Jahr
https://www.astrazeneca.com/media-centre/press-releases/2024/q1-2024-results.html
https://www.astrazeneca.com/media-centre/press-releases/2024/q1-2024-results.html
Financial performance for Q1 2024 (Growth numbers at CER):
- Total Revenue up 19% to $12,679m, driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines
- Double-digit growth in Total Revenue from Oncology at 26%, CVRM at 23%, R&I at 17%, and Rare Disease at 16%.
- Core Product Sales Gross Margin3 of 82%
- Core Operating Margin of 34%
- Core Tax Rate of 21%
- Core EPS increased 13% to $2.06. The increase in Core EPS was lower than Total Revenue growth principally due to a $241m gain in the prior year period on the disposal of Pulmicort Flexhaler US rights
- Total Revenue and Core EPS guidance at CER for FY 2024 reiterated
Die Börse honoriert heute die guten Geschäftszahlen und setzt den Anstieg der Aktie der letzten Tage fort.
.